Drug | Study | ORR | mPFS | Reference |
Atezolizumab | NCT02367794 (IMPower 131), N = 1021 (phase III), atezolizumab + chemotherapy vs. Placebo + chemotherapy | 49.7% vs. 41% | 6.3 vs. 5.6 mo. | Jotte et al. 2020 [18] |
Atezolizumab | NCT02366143 (IMPower 150), N = 1202 (phase III), atezolizumab + bevacizumab + chemotherapy vs. Placebo + bevacizumab + chemotherapy | 63.5% vs. 48.8% | 8.3 vs. 6.8 mo. | Socinski et al. 2018 [19] |
Pembrolizumab | NCT02775435 (Keynote-407), N = 559 (phase III), pembrolizumab + chemo-therapy vs. placebo + chemo-therapy (squamous) | 57.9% vs. 38.4% | 6.4 vs. 4.8 mo. | Paz-Ares et al. 2018 [20] |
Pembrolizumab | NCT 02578680 (Keynote-189), N = 616 (phase III), pembrolizumab + chemotherapy vs. placebo + chemotherapy (adeno) | 47.5% vs. 18.9% | 8.8 vs. 4.9 mo. | Gandhi et al. 2018 [21] |
Durvalumab | NCT03164616 (POSEIDON), N = 1013 (phase III), durvalumab + chemotherapy vs. chemotherapy | 37.3% vs. 25.6% | 5.5 vs. 4.8 mo. | Johnson et al. 2021 [22] |